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a b s t r a c t
Evidence suggests that the cerebellum contributes to cognition as well as motor function. We investi-
gated cerebellar grey matter (GM) and white matter (WM) changes from magnetic resonance images in
dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and healthy older subjects using voxel-
based morphometry (VBM). Subjects (39 controls, 41 DLB, and 48 AD) underwent magnetic resonance
imaging as well as clinical and cognitive assessments. VBM used SPM8 with a cerebellar brain mask to
deﬁne the subspace for voxel analysis. Statistical analyses were conducted using the general linear
model. Relative to ﬁndings in controls, VBM analysis revealed cerebellar GM loss in lobule VI bilaterally
in AD and in left Crus I and right Crus II regions in DLB. WM deﬁcits were conﬁned to AD in the bilateral
middle cerebellar peduncles. DLB demonstrates a different pattern of cerebellar GM loss which, although
not signiﬁcantly different from that in AD, could be an important feature in understanding the
neurobiology of DLB and warrants further investigation.
& 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
To date, voxel based morphometry (VBM) studies in patients
with dementia with Lewy bodies (DLB) when contrasted against
patients with Alzheimer's disease (AD) have focussed on volu-
metric changes within the cerebrum. Patterns of cortical atrophy
in AD are typically in the medial temporal lobe and temporopar-
ietal association cortices (Burton et al., 2002; Karas et al., 2003;
Whitwell et al., 2007; Takahashi et al., 2010; Watson et al., 2012).
In DLB, there is some overlap with the AD pattern, but atrophy is
less diffuse, with relative preservation of the medial temporal lobe
(Burton et al., 2002; Karas et al., 2003; Whitwell et al., 2007;
Takahashi et al., 2010; Watson et al., 2012), and there is also
evidence of greater subcortical atrophy (Cousins et al., 2003;
Hanyu et al., 2007; Whitwell et al., 2007).
What is less established, however, is whether there are volu-
metric changes in the cerebellum in DLB. This is an important
question as it is now recognised that the cerebellum has a
signiﬁcant role beyond sensorimotor control in cognition and
affect (Schmahmann and Caplan, 2006). For example, there is
evidence that the cerebellum, by means of extensive cerebellar-
cortical connections, participates in distributed cognitive networks
which include structures such as the prefrontal and parietal
association cortices (Stoodley, 2012). Functionally, these networks
may impact executive functioning and predictive motor timing,
both of which may have important implications for conditions
such as Parkinson's disease and, by extension, DLB (Husarova et al.,
2013; Nombela et al., 2013).
Pathologically, cerebellar atrophy has been observed in other
related alpha-synuclein pathologies such as Parkinson's disease
(Pereira et al., 2009), multi-system atrophy with cerebellar features
and idiopathic rapid eye movement (REM) sleep behaviour disorder
(iRBD) (Schulz et al., 1994). Cerebellar volumetric and grey matter
(GM) density reductions have been observed in progressive supra-
nuclear palsy (Agosta et al., 2010; Messina et al., 2011; Giordano et al.,
2013) as well as conditions such as schizophrenia (Chua et al., 2007;
Kuhn et al., 2012), thus further highlighting the potential importance
of the cerebellum in diseases with signiﬁcant cognitive, motor and
neuropsychiatric sequelae. In DLB, cerebellar alpha-synuclein deposi-
tion affecting both purkinje and glial cells has been reported (Mori et
al., 2003), and more recently, functional metabolic and perfusion
imaging changes have suggested that cerebellar uptake along with
uptake in other motor areas may be associated with cognitive and
attentional ﬂuctuations (Taylor et al., 2013) as well as visual hallucina-
tions (Miyazawa et al., 2010).
Volumetric cerebellar changes in DLB, however, have not been
systematically reported. Therefore, in the present study we per-
formed separate GM and white matter (WM) assessment of the
cerebellum in DLB, AD and healthy older subjects as well as their
clinical correlates using diffeomorphic anatomical registration
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with exponentiated Lie algebra (DARTEL) voxel-based morphome-
try (VBM).
2. Methods
2.1. Participants
Eighty-eight individuals over the age of 60 (47 subjects with probable AD
(McKhann et al., 1984), 41 with probable DLB (McKeith et al., 2005)) were recruited
from a community dwelling population of patients referred to local Old Age
Psychiatry, Geriatric Medicine or Neurology Services. All subjects underwent
clinical and neuropsychological assessments. Thirty-nine healthy controls of similar
ages were recruited from among relatives and friends of patients with dementia.
The research was approved by the local ethics committee. All subjects or, where
appropriate, their nearest relative provided written informed consent. Exclusion
criteria for all subjects included contra-indications for magnetic resonance imaging
(MRI), previous history of alcohol or substance misuse, signiﬁcant neurological or
psychiatric history, focal brain lesions on brain imaging, or the presence of other
severe or unstable medical illness.
Assessment of global cognitive measures included the Cambridge Cognitive
Examination (CAMCOG), incorporating the Mini-Mental State Examination (MMSE)
(Folstein et al., 1975). Motor parkinsonism was measured with the Uniﬁed
Parkinson's Disease Rating Scale Part III (UPDRS-III) (Fahn and Elton, 1987). For
participants with dementia, neuropsychiatric features were assessed using the
Neuropsychiatric Inventory (NPI) (Cummings et al., 1994), while cognitive ﬂuctua-
tions were examined using the clinician's assessment of ﬂuctuation (Walker et al.,
2000).
2.2. MRI data acquisition
All subjects underwent T1-weighted MR scanning on a 3-Tesla MRI system
using an eight-channel head coil (Intera Achieva scanner, Philips Medical Systems,
Eindhoven, Netherlands). The dataset was generated from two independent
imaging cohorts (cohort 1: controls 23, AD 31, DLB 23; cohort 2: controls 16, AD
16, DLB 18) with slightly different T1 sequences. The sequence for cohort 1 was as
follows: whole brain, 3D MPRAGE, sagittal acquisition, matrix size 216 (anterior–
posterior)208 (superior–inferior)180 (right–left), repetition time (TR)¼8.3 ms,
echo time (TE)¼4.6 ms, inversion time (TI)¼1250 ms, ﬂip angle¼81, SENSE
factor¼2, voxel output 111 mm3. The sequence for cohort 2 was as follows:
whole brain, 3D MPRAGE, sagittal acquisition, matrix size 240 (anterior–poster-
ior)240 (superior–inferior)150 (right–left), TR¼9.6 ms, TE¼4.6 ms,
TI¼1250 ms, ﬂip angle¼81, SENSE factor¼2, voxel output 0.940.941.2 mm3.
2.3. VBM-DARTEL analysis
VBM analysis was conducted using SPM8 (http://www.ﬁl.ion.ucl.ac.uk/spm)
running on MATLAB 7.9 (Math-Works, Natick, MA, USA). First, MR images were
segmented into GM, WM and cerebrospinal ﬂuid (CSF) using SPM8's standard
uniﬁed segmentation module (Ashburner and Friston, 2005). Second, population
templates (GM, WM) were derived from the entire image dataset using the DARTEL
technique (Ashburner, 2007). Third, after an initial afﬁne registration of the DARTEL
templates to the corresponding tissue probability maps in Montreal Neurological
Institute (MNI) space (http://www.mni.mcgill.ca/), non-linear warping of the
segmented images was then performed to match the corresponding MNI space
DARTEL templates (GM, WM). Fourth, images were modulated to ensure that
relative volumes of GM and WM were preserved following spatial normalisation.
Lastly, images were smoothed with an 8-mm full width at half maximum Gaussian
kernel. After spatial pre-processing, the smoothed, modulated, normalised imaging
datasets were then used for voxelwise statistical analysis.
2.4. Statistical analysis
Group differences in GM and WM volumes were assessed using the general
linear model in SPM8, and statistical signiﬁcance was estimated from the distribu-
tional approximations of Gaussian random ﬁelds (Friston et al., 1994). Age and total
intracranial volume (TIVSPM8) were entered into the design matrix as nuisance
variables. Multiple regression analyses were also performed to investigate effects of
GM and WM loss on clinical and cognitive variables separately in AD and DLB. A
cerebellum binary mask image obtained from the Wake Forest University Pickatlas
toolbox (http://fmri.wfubmc.edu/software/PickAtlas) deﬁned the brain volume
subspace for all voxel analyses. Signiﬁcant effects were identiﬁed using an
uncorrected threshold (Puncorrectedr0.001), followed by correction for multiple
comparisons using the family-wise error (FWE) (PFWEr0.05) within the cerebellar
volume subspace.
For demographic and clinical data, the Statistical Package for the Social Sciences
software (SPSS ver. 19.0.0.1, http://www-01.ibm.com/software/analytics/spss/) was
used for further statistical evaluation. Continuous variables were tested for
normality using the Shapiro–Wilk test and visual inspection of variable histograms,
and assessed where appropriate using parametric (analysis of variance, ANOVA)
and non-parametric (Kruskal–Wallis) procedures. For categorical data, χ2 tests
were applied.
3. Results
3.1. Subject characteristics
Table 1 shows demographic and group characteristics. Groups
were matched for age and gender. CAMCOG and MMSE scores
were similar between AD and DLB patients but signiﬁcantly
differed from scores of controls. As expected, UPDRS III measures
were signiﬁcantly higher in DLB patients than in AD patients and
controls. NPI, NPI_hallucinations, CAF scores and frequency of RBD
were all signiﬁcantly greater in DLB than AD. The proportion of
individuals receiving cholinesterase inhibitors did not signiﬁcantly
differ between dementia groups.
Table 1
Demographic and group characteristics.
Control AD DLB Statistic, P value
n 39 47 41
Gender (m: f) 25: 14 33: 14 26: 15 χ2¼0.6, 0.8
Age (years) 77.076.4 79.078.8 78.676.2 F2,124¼0.8, 0.4
MMSE 29.071.0 20.874.0 20.975.0 F2,124¼62.0, o0.001†
CAMCOG 96.573.3 67.8713.5 69.5714.9 F2,124¼74.1, o0.001†
NPI total Na 9.378.7 13.5711.0 U88¼1026.5, 0.04
NPI_hall Na 0.270.8 2.172.1 U88¼1521.0, o0.001
RBD (y: n) 0: 39 1: 46 23: 18 χ2¼22.6, o0.001n
UPDRS III 1.271.7 2.672.4 24.4713.7 H2¼86.1, o0.001††
CAF Na 1.573.0 5.974.7 U88¼1380.5, o0.001
ChI use (y: n) Na 40: 7 32: 9 χ2¼0.7, 0.4
TIVspm8 (ml) 1500.07133.8 1495.47134.0 1525.07154.4 F2,124¼0.4, 0.6
Bold text denotes statistical signiﬁcance.
Values expressed as Mean71 S.D.
MMSE¼Mini Mental State Examination, CAMCOG¼Cambridge Cognitive Examination, NPI¼Neuropsychiatric Inventory, NPI_hall¼NPI hallucinations, RBD¼REM sleep
behaviour disorder, UPDRS III¼Uniﬁed Parkinson's Disease Rating Scale (section III), ChI¼cholinesterase inhibitor, TIV¼total intracranial volume. CAF¼Clinical Assessment
of Fluctuation. Na¼not applicable.
Post-hoc tests:
n AD vs. DLB.
† Con4AD, DLB (Po0.001), AD vs. DLB (P40.10) (Gabriel's).
†† DLB4Con, AD (Po0.001), Con vs. AD (P¼0.14) (Mann–Whitney U).
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3.2. Cerebellar GM and WM analysis
Relative to ﬁndings in controls, SPM8 revealed signiﬁcant
cerebellar GM loss in AD in lobule VI bilaterally, extending into
parahippocampal and fusiform structures (Fig. 1A, green map,
PFWEr0.05). In DLB, a different pattern of GM loss emerged
compared with controls in the left Crus I and right Crus II regions,
extending to a lesser extent into fusiform structures (Fig. 1A, red
map, PFWEr0.05). Signiﬁcant differences were not observed,
however, between AD and DLB for either contrast (AD4DLB,
DLB4AD), and cerebellar GM atrophy in controls did not exceed
that of AD or DLB. In WM, deﬁcits were observed in AD partici-
pants in the bilateral middle cerebellar peduncles and the left
inferior cerebellar peduncle (Fig. 1B, green map, PFWEr0.05). No
WM deﬁcits were identiﬁed in controls that were greater than
those in AD. WM loss did not signiﬁcantly differ between DLB and
controls or among dementia groups for any contrasts (Con4DLB,
DLB4Con, AD4DLB, DLB4AD). Table 2 shows the location and
peak signiﬁcance of statistical maps across selected groups. There
were no signiﬁcant associations between any clinical and cognitive
measures (CAMCOG, MMSE, NPI, UPDRS III and CAF scores) and
GM volume in AD or DLB. Effects of WM volume loss on these
variables were also examined in AD and DLB, yielding non-
signiﬁcant results.
To characterise the cerebellar results, whole-brain difference
maps between groups depicting AD loss compared with controls
(Con4AD), DLB loss relative to controls (Con4DLB) and AD loss
compared with DLB (DLB4AD) are also presented for GM (Fig. 1C)
and WM (Fig. 1D).
4. Discussion
To our knowledge, this was the ﬁrst study to investigate and
observe patterns of cerebellar GM and WM atrophy in DLB and AD
compared with healthy subjects of similar age using DARTEL-VBM.
Two results emerged from this analysis. First, DLB had a pattern of
cerebellar GM loss distinct but not signiﬁcantly different from AD.
Second, compared with ﬁndings in controls, WM cerebellar
deﬁcits were apparent in AD but not in DLB. GM matter loss has
been previously reported across the continuum from mild cogni-
tive impairment to AD (Thomann et al., 2008; Dos Santos et al.,
2011; Spulber et al., 2012; Moller et al., 2013), and thus our
ﬁndings are consistent with these. Since total GM volumes are
proportional to total WM volumes in both AD and DLB (AD:
r¼0.55, Po0.001; DLB: r¼0.63, Po0.001), WM loss in AD was
not unexpected given the loss of cortico-cerebellar connections
that are likely to occur as a result of the signiﬁcant cortical GM loss
under this condition which could impact upon the widespread
connectivity between the cortex and cerebellum. By similar argu-
ment, there was less cortical atrophy in DLB, and this may
potentially explain the lack of cerebellar WM loss observed in
Fig. 1. Signiﬁcant cerebellar GM loss in AD (green) and DLB (red) relative to healthy older subjects (A). Signiﬁcant cerebellar WM loss in AD relative to healthy older subjects
(B). Whole brain maps depicting signiﬁcant regions of GM (C) and WM (D) loss between groups. Results superimposed on a MRI T1 brain template image (L¼ left, R¼right).
(For interpretation of the references to colour in this ﬁgure legend,the reader is referred to the web version of this article)
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DLB compared with controls. The pattern of GM loss in DLB
compared with the pattern in controls primarily involved the
posterior and lateral cerebellum, areas which have been associated
with cognitive functions such as executive function and working
memory (Stoodley et al., 2010), and atrophy in these areas has
also been implicated in psychopathology and thought disorder
observed in schizophrenia (Schmahmann, 1991; Andreasen
et al., 1998) as well as with cerebellar ‘dysmetria of thought’
(Schmahmann, 1991); the latter is a concept that implies that in
addition to the canonical motor function of the cerebellum to
regulate force, rhythm, timing and accuracy of movement, the
cerebellum also performs an analogous regulatory role for higher
cognitive and mental functions (Schmahmann, 1998).
In the present study, we did not observe any associations
between the severity of volumetric change (GM or WM) and a
wide range of clinical variables including cognitive and neuropsy-
chiatric measures in either DLB or AD. It could be that the
observed cerebellar structural changes are epiphenomena which
are not central to the clinical phenotypes seen in either disease
state or that cerebellar atrophy, in itself, is not necessarily relevant
to cognitive and neuropsychiatric symptoms in DLB/AD, but more
a representation of the broader neurodegenerative disease pro-
cess. However, alterations in functional state of the cerebellum
rather than structure may be more salient to cognitive and
psychiatric symptomatology in DLB; for example, there is a
reported association between cerebellar hypermetabolism in DLB
and visual hallucinations (Miyazawa et al., 2010). Alternatively, it
may be that the role of the cerebellum should be considered as
only one element in a distributed cognitive-motor network given
the major inter-connection between the cerebellum and the
cerebrum (Miyazawa et al., 2010); thus, multivariate network
approaches may be more sensitive in elucidating any cerebellar
contribution to the cognitive/neuropsychiatric phenotypes of DLB
(Taylor et al., 2013). Finally, it may also be that the global clinical
assessments applied in the present study (e.g., CAMCOG and
MMSE) are not speciﬁc to those cognitive or neuropsychiatric
features which may depend upon cerebellar function; for example,
there may be a need for speciﬁc tests that tune into cognitive
domains known to be sensitive to cerebellar dysfunction such as
working memory tasks (Tomlinson et al., 2014). Similarly the
application of more detailed neuropsychological test batteries that
are sensitive and speciﬁc to the differing cognitive proﬁles of AD
and DLB may help delineate what functions may map onto speciﬁc
patterns of cerebellar atrophy.
In comparison of the two forms of dementia, we observed no
signiﬁcant differential patterns of cerebellar atrophy between AD
and DLB despite different patterns of atrophy compared with
controls. The absence of a differential pattern for each disorder
is unlikely to have been driven by type II errors given our relatively
large patient samples; rather, it could reﬂect the heterogeneity in
the degree of cerebellar loss seen in these dementias and com-
monalities between AD and DLB in terms of neurogenerative
processes such as amyloid deposition (Quigley et al., 2011). Our
ﬁndings of volumetric changes in the cerebellum may also have
implications for functional imaging studies in dementia, where
this structure has been used as a reference region for image-
intensity normalisation (Lacalle-Aurioles et al., 2013).
Strengths of the current study include the following: relatively
large AD and DLB cohorts, 3-Tesla MRI dataset, and rigorous and
validated methodologies for imaging. Patients were diagnostically
classiﬁed by two independent raters, and underwent detailed
clinical and cognitive assessment. The data also comprised two
slightly different T1 sequences, so in addition to age and TIV,
sequence was also included as a nuisance covariate; however, this
did not affect results and was therefore excluded from the model.
One potential weakness may lie in the inter-subject cerebellar
spatial normalisation that was implemented by the whole-
brain DARTEL algorithm rather than a cerebellum-optimised
approach (Diedrichsen, 2006). The optimised procedure uses
spatially unbiased templates that could offer increased sensitivity,
though this did not appear to be a limiting factor in the present
study. In conclusion, we observed clear volumetric cerebellar
losses in both DLB and AD compared with controls, suggesting
that this structure is affected by the neurogenerative processes in
both disease states. The potential impact of cerebellar pathology in
the broader clinical phenotype of the two conditions warrants
further consideration.
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